Stryker Corporation (NYSE:SYK)‘s stock had its “hold” rating reaffirmed by equities researchers at BMO Capital Markets in a research report issued on Tuesday, July 11th. They presently have a $140.00 target price on the medical technology company’s stock. BMO Capital Markets’ price target would indicate a potential downside of 5.28% from the company’s current price.
Other equities analysts have also issued research reports about the company. Deutsche Bank AG reissued a “buy” rating and set a $148.00 price target (up previously from $135.00) on shares of Stryker Corporation in a report on Saturday, April 29th. BidaskClub lowered Stryker Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Stryker Corporation in a report on Monday, June 19th. Jefferies Group LLC reissued a “hold” rating and set a $132.00 price target on shares of Stryker Corporation in a report on Thursday, April 13th. Finally, Goldman Sachs Group, Inc. (The) initiated coverage on Stryker Corporation in a report on Tuesday, May 16th. They set a “neutral” rating and a $129.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $143.87.
Stryker Corporation (NYSE:SYK) opened at 147.80 on Tuesday. Stryker Corporation has a one year low of $106.48 and a one year high of $148.15. The stock has a 50 day moving average price of $142.41 and a 200 day moving average price of $133.92. The firm has a market cap of $55.26 billion, a PE ratio of 32.99 and a beta of 0.79.
Stryker Corporation (NYSE:SYK) last released its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.58% and a net margin of 14.22%. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. During the same quarter last year, the company posted $1.39 earnings per share. The business’s revenue was up 6.1% on a year-over-year basis. Equities research analysts expect that Stryker Corporation will post $6.43 EPS for the current year.
WARNING: “Stryker Corporation (NYSE:SYK) Stock Rating Reaffirmed by BMO Capital Markets” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/07/30/stryker-co-nysesyk-given-hold-rating-at-bmo-capital-markets-updated-updated.html.
In other news, insider David Floyd sold 19,305 shares of the firm’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Timothy J. Scannell sold 13,322 shares of the firm’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was sold at an average price of $135.89, for a total transaction of $1,810,326.58. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,008 shares of company stock valued at $5,669,088. Insiders own 7.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SYK. Private Asset Management Inc. boosted its position in shares of Stryker Corporation by 4.8% in the first quarter. Private Asset Management Inc. now owns 8,800 shares of the medical technology company’s stock worth $1,159,000 after buying an additional 400 shares during the period. First Financial Bank N.A. Trust Division boosted its stake in Stryker Corporation by 6.9% in the first quarter. First Financial Bank N.A. Trust Division now owns 49,328 shares of the medical technology company’s stock valued at $6,494,000 after buying an additional 3,199 shares during the last quarter. Pensionfund DSM Netherlands purchased a new stake in Stryker Corporation during the first quarter valued at approximately $4,002,000. Toth Financial Advisory Corp boosted its stake in Stryker Corporation by 0.6% in the first quarter. Toth Financial Advisory Corp now owns 77,031 shares of the medical technology company’s stock valued at $10,141,000 after buying an additional 471 shares during the last quarter. Finally, Pensionfund Sabic purchased a new stake in Stryker Corporation during the first quarter valued at approximately $2,014,000. 74.26% of the stock is owned by institutional investors and hedge funds.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Stock Ratings for Stryker Corporation Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.